A recent study calculated the incidence and mortality rates for patients with Medicaid coverage who had nonventilator hospital-acquired pneumonia (NVHAP) and found possible associations between greater health care costs and NVHAP diagnosis.
Although efforts have reduced the rates of many hospital-acquired infections (HAI), similar effort has not seen toward decreasing rates of nonventilator hospital-acquired pneumonia (NVHAP), despite NVHAP’s correlation with substantial mortality and health care costs for patients in acute care.
Published in American Journal of Infection Control, study results revealed an NVHAP incidence of 2.63 per 1000 patient-days, a 7.76% morality rate, and $20,189 in additional costs over a 5-year period for patients with NVHAP who have Medicaid coverage.
An inpatient NVHAP diagnosis was defined as a pneumonia diagnosis 48 hours or more after admission to a hospital. Pneumonia must not have been present at the time of admission nor associated with mechanical ventilation.
Inpatient and outpatient medical care, dental services, and administrative claims data were collected from the IBM Watson MarketScan Medicaid Database across 13 states. This study included all Medicaid beneficiaries admitted to a hospital at some point between 2015 and 2019.
From 2015 to 2019, 75,909 of 5,668,417 Medicaid beneficiaries were given an NVHAP diagnosis, which translated into the overall NVHAP incidence of 2.63 per 1000 patient-days.
Patients aged 45 to 64 years made up 19.1% of the study sample but had the highest NVHAP incidence of 5.18 per 1000 patient-days. A slightly lower NVHAP incidence of 4.47 per 1000 patient-days was found in patients 65 years or older. Patients aged 0 to 17 years had the lowest NVHAP incidence of 0.71 per 1000 patient-days. These data suggest that younger patients are at risk for NVHAP although they are not generally thought to be, the researchers noted.
In addition, male patients had a higher NVHAP incidence compared with female patients, despite the study including about twice as many women (n = 3,625,421) as men (n = 1,971,500). The NVHAP incidence for males was 3.1 per 1000 patient-days vs 2.32 among females.
The overall NVHAP 5-year mortality rate (from 2015 to 2019) was 7.76%. By age, the highest mortality rates were 9.39%, which was seen among patients 65 years or older, and 8.64% found in patients aged 45 to 64 years.
After a diagnosis of NVHAP, total health care costs as a percentage of total NVHAP encounters increased by 28.8%. Costs as a percentage of total inpatient costs increased by 14.6%.
A limitation of this study is that variable accuracy could not be confirmed because of the use of administrative claims data and diagnostic-related group codes to verify pneumonia diagnoses. The researchers also noted that a pneumonia diagnosis is not always straightforward. In addition, study results are not generalizable to populations beyond Medicaid beneficiaries. As the results of this study are purely descriptive, interpretations of these findings are limited.
“These NVHAP incidence and cost findings are consistent with previous research, providing further support that NVHAP prevention in the United States health care system is a critical patient safety issue,” the researchers concluded.
Reference
Giuliano KK, Baker D, Thakkar-Samtani M, Scannapieco FA, Heaton LJ, Frantsve-Hawley J. Incidence, mortality, and cost trends in nonventilator hospital-acquired pneumonia in Medicaid beneficiaries, 2015-2019. Am J Infect Control. Published online June 19, 2022. doi:10.1016/j.ajic.2022.06.016
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More
Congress Urged to Repeal Comstock Act Threatening Reproductive Rights and Public Health
May 16th 2024In a joint letter addressed to Congress, Healthcare Across Borders, Take Back the Court Action Fund, and UltraViolet Action called out the resurgence of the Comstock Act, urging immediate action to repeal this century-old law that threatens reproductive rights and public health in the US.
Read More